Micro RNA Expression and Prognosis in Low-grade Non-invasive Urothelial Carcinoma
Carregando...
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
BRAZILIAN SOC UROL
Citação
International Braz J Urol, v.40, n.5, p.644-649, 2014
Resumo
Purpose: To analyze a possible correlation between a miRNA expression profile and important prognostic factors for pTa urothelial carcinomas (UC), including tumor size, multiplicity and episodes of recurrence. Materials and Methods: Thirty low-grade non-invasive pTa bladder UC from patients submitted to transurethral resection were studied, in a mean follow-up of 17.7 months. As controls, we used normal bladder tissue from five patients submitted to retropubic prostatectomy to treat benign prostatic hyperplasia. Extraction, cDNA and amplification were performed for 14 miRNAs (miR-100, -10a, -21, -205, -let7c, -143, -145, -221, -223, -15a, -16, -199a and -452) using specific kits, and RNU-43 and -48 were used as endogenous controls. Statistical tests were used to compare tumor size, multiplicity and episodes of recurrence with miRNAs expression profiles. Results: There was a marginal correlation between multiplicity and miR-let7c over- expression. For all others miRNA no correlation between their expression and prognostic factors was found. Conclusion: We did not find differences for miRNAs expression profiles associated with prognostic factors in tumor group studied. The majority of miRNAs are down-regulated, except miR-10a, over-expressed in most of cases, seeming to have increased levels in tumor with more unfavorable prognostic factors. More studies are needed in order to find a miRNA profile able to provide prognosis in pTa UC to be used in clinical practice.
Palavras-chave
MicroRNAs, Urinary Bladder Neoplasms, Prognosis, Molecular Biology
Referências
- Ali-El-Dein B, 2003, BJU INT, V92, P393, DOI 10.1046/j.1464-410X.2003.04360.x
- Bakkar AA, 2003, CANCER RES, V63, P8108
- Borden LS, 2005, CURR OPIN ONCOL, V17, P275, DOI 10.1097/01.cco.0000156985.47984.9e
- Botteman MF, 2003, PHARMACOECONOMICS, V21, P1315
- Castillo-Martin M, 2010, UROL ONCOL-SEMIN ORI, V28, P401, DOI 10.1016/j.urolonc.2009.04.019
- Catto JWF, 2009, CANCER RES, V69, P8472, DOI 10.1158/0008-5472.CAN-09-0744
- Cimmino A, 2006, P NATL ACAD SCI USA, V103, P2464, DOI 10.1073/pnas.0510793103
- Dip N, 2012, J UROLOGY, V188, P1951, DOI 10.1016/j.juro.2012.07.004
- Dip N, 2011, J MOL BIOMARK DIAGN, V2, P1
- Enokida H, 2008, INT J CLIN ONCOL, V13, P298, DOI 10.1007/s10147-008-0811-1
- Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705
- Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
- Lamm DL, 2000, J UROLOGY, V163, P1124, DOI 10.1016/S0022-5347(05)67707-5
- Leite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P265, DOI 10.1016/j.urolonc.2009.02.002
- Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
- Lin TX, 2009, J UROLOGY, V181, P1372, DOI 10.1016/j.juro.2008.10.149
- Marsit CJ, 2007, CARCINOGENESIS, V28, P1745, DOI 10.1093/carcin/bgm116
- Martinez-Torrecuadrada JM, 2005, CLIN CANCER RES, V11, P6280, DOI 10.1158/1078-0432.CCR-05-0282
- McConkey DJ, 2010, UROL ONCOL-SEMIN ORI, V28, P429, DOI 10.1016/j.urolonc.2010.04.008
- NARAYANA AS, 1983, J UROLOGY, V130, P56
- Ornitz DM, 1996, J BIOL CHEM, V271, P15292
- Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001
- Pandith AA, 2013, UROL ONCOL-SEMIN ORI, V31, P398, DOI 10.1016/j.urolonc.2010.07.014
- Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
- SOLOWAY MS, 1980, CANCER, V45, P1856
- van Rhijn BWG, 2001, CANCER RES, V61, P1265
- Veerla S, 2009, INT J CANCER, V124, P2236, DOI 10.1002/ijc.24183
- Zhang ZT, 2001, ONCOGENE, V20, P1973, DOI 10.1038/sj.onc.1204315